Violation Tracker Summary for Primary Offense Type

Offense Type: 
off-label or unapproved promotion of medical products
Penalty Total since 2000: 
Number of Penalty Records: 
The totals here are adjusted to account for the fact that each parent's entries may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. They are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the individual records list below.

Top 10 Parent CompaniesTotal Penalty $Number of Records
Johnson & Johnson$3,136,000,00010
Eli Lilly$1,608,100,0009
Merck KGaA (EMD)$704,000,0002
Bristol-Myers Squibb$534,500,0003

Individual Penalty Records:

Click on the company or penalty amount for more information on each case. Click on the parent name to reach the summary page for that parent company.
Download results as CSV or XML
Company Parent Parent Major Industry Year Agency Penalty Amountsort icon
Warner-Lambert Pfizer pharmaceuticals 2004 FDA $430,000,000
Schering-Plough Corporation Merck pharmaceuticals 2006 USAO $435,000,000
GlaxoSmithKline GlaxoSmithKline pharmaceuticals 2012 MULTI-AG (*) $477,792,391
Wyeth Pharmaceuticals Inc. Pfizer pharmaceuticals 2013 FDA $490,900,000
Google Inc. Alphabet Inc. information technology 2011 FDA $500,000,000
Bristol-Myers Squibb Company Bristol-Myers Squibb pharmaceuticals 2007 DOJ_CIVIL $515,000,000
AstraZeneca LP AstraZeneca pharmaceuticals 2010 FDA $520,000,000
Johnson & Johnson Johnson & Johnson pharmaceuticals 2013 MULTI-AG (*) $541,000,000
Allergan Inc. AbbVie pharmaceuticals 2010 FDA $600,000,000
Amgen Inc. Amgen pharmaceuticals 2012 MULTI-AG (*) $612,000,000
Serono, S.A. Merck KGaA (EMD) pharmaceuticals 2005 FDA $704,000,000
Amgen Inc. Amgen pharmaceuticals 2012 FDA $762,000,000
Merck, Sharp & Dohme Merck pharmaceuticals 2011 FDA $950,000,000
Eli Lilly and Company Eli Lilly pharmaceuticals 2009 FDA $1,415,000,000
Abbott Laboratories Inc. AbbVie pharmaceuticals 2012 FDA $1,500,000,000
Johnson & Johnson Johnson & Johnson pharmaceuticals 2013 FDA $2,200,000,000
Pfizer Inc. Pfizer pharmaceuticals 2009 FDA $2,300,000,000
GlaxoSmithKline LLC GlaxoSmithKline pharmaceuticals 2012 FDA $3,000,000,000
Download results as CSV or XML
(*): Some penalties are partial or complete duplicates of other penalty records, either because a DOJ settlement duplicates an agency record or because EPA listed the full penalty for a company for each of the company's relevant facilities. Penalty amounts marked with an asterisk have been identified by Good Jobs First as duplicating other penalty amounts.